Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet?
Neurath M, Sands BE, Rieder F (2024)
Publication Type: Journal article
Publication year: 2024
Journal
Article Number: gutjnl-2024-332919
DOI: 10.1136/gutjnl-2024-332919
Abstract
Despite significant advances in biologic and small molecule treatments and the emergence of combination therapies to treat inflammatory bowel diseases (IBD) a large unmet need remains to control intestinal inflammation. New approaches targeting several pathways simultaneously with a favorable safety profile and agents that trigger anti-inflammatory pathways to drive durable resolution of inflammation are needed. This article discusses novel cellular immunotherapies and immune cell depleting therapies in IBD, including CAR-T cell approaches, Tr1 and T regulatory (Treg) cells and cell depleting antibodies such as rosnilimab. These novel approaches have the potential to overcome current therapeutic limitations in the treatment of IBD.
Authors with CRIS profile
Involved external institutions
United States (USA) (US)How to cite
APA:
Neurath, M., Sands, B.E., & Rieder, F. (2024). Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet? Gut. https://doi.org/10.1136/gutjnl-2024-332919
MLA:
Neurath, Markus, Bruce Eric Sands, and Florian Rieder. "Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet?" Gut (2024).
BibTeX: Download